463 related articles for article (PubMed ID: 19195685)
41. Hypercoagulability markers in young asymptomatic heterozygous carriers of factor V Leiden (G1691A) or prothrombin (G20210A) variant.
Godoi LC; Fernandes AP; Vieira LM; Melgaço DA; de Bastos M; Ribeiro Mde F; Carvalho Md; Dusse LM
Clin Chim Acta; 2006 Mar; 365(1-2):304-9. PubMed ID: 16256098
[TBL] [Abstract][Full Text] [Related]
42. The G1691A mutation of the factor V gene (factor V Leiden) and the G20210A mutation of the prothrombin gene as risk factors in thrombotic microangiopathies.
Sucker C; Kurschat C; Hetzel GR; Grabensee B; Maruhn-Debowski B; Loncar R; Ostojic L; Scharf RE; Zotz RB
Clin Appl Thromb Hemost; 2009; 15(3):360-3. PubMed ID: 19448164
[TBL] [Abstract][Full Text] [Related]
43. Factor IX-Padua enhances the fibrinolytic resistance of plasma clots.
Ammollo CT; Semeraro F; Colucci M; Simioni P
Thromb Haemost; 2014 Feb; 111(2):226-32. PubMed ID: 24136406
[TBL] [Abstract][Full Text] [Related]
44. Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demonstrates the importance of CPU stability over proCPU concentration in down-regulating fibrinolysis.
Knecht W; Willemse J; Stenhamre H; Andersson M; Berntsson P; Furebring C; Harrysson A; Hager AC; Wissing BM; Hendriks D; Cronet P
FEBS J; 2006 Feb; 273(4):778-92. PubMed ID: 16441664
[TBL] [Abstract][Full Text] [Related]
45. Hyperprothrombinaemia-induced APC resistance: differential influence on fibrin formation and fibrinolysis.
Binetti BM; Rotunno C; Tripodi A; Asti D; Semeraro F; Semeraro N; Colucci M
Thromb Haemost; 2006 Apr; 95(4):606-11. PubMed ID: 16601829
[TBL] [Abstract][Full Text] [Related]
46. Superficial vein thrombosis of lower limbs: influence of factor V Leiden, factor II G20210A and overweight.
de Moerloose P; Wutschert R; Heinzmann M; Perneger T; Reber G; Bounameaux H
Thromb Haemost; 1998 Aug; 80(2):239-41. PubMed ID: 9716145
[TBL] [Abstract][Full Text] [Related]
47. Inherited thrombophilic risk factors in a large cohort of individuals referred to Italian thrombophilia centers: distinct roles in different clinical settings.
Margaglione M; Brancaccio V; Ciampa A; Papa ML; Grandone E; Di Minno G
Haematologica; 2001 Jun; 86(6):634-9. PubMed ID: 11418373
[TBL] [Abstract][Full Text] [Related]
48. Thrombophilic risk factors and peripheral arterial disease severity.
Sartori M; Favaretto E; Legnani C; Cini M; Conti E; Amato A; Palareti G
Thromb Haemost; 2010 Jul; 104(1):71-7. PubMed ID: 20390230
[TBL] [Abstract][Full Text] [Related]
49. Laboratory assessment of hypercoagulable state. A study in a group of patients with venous thromboembolism born in Chioggia.
Gessoni G; Valverde S; Canistro R; Trabuio E; Antico F; Manoni F
Minerva Med; 2007 Apr; 98(2):89-93. PubMed ID: 17519850
[TBL] [Abstract][Full Text] [Related]
50. Increased risk of intraventricular hemorrhage in preterm infants with thrombophilia.
Petäjä J; Hiltunen L; Fellman V
Pediatr Res; 2001 May; 49(5):643-6. PubMed ID: 11328946
[TBL] [Abstract][Full Text] [Related]
51. Factor V G1691A, prothrombin G20210A and methylenetetrahydrofolate reductase polymorphism C677T are not associated with coronary artery disease and type 2 diabetes mellitus in western Iran.
Rahimi Z; Nomani H; Mozafari H; Vaisi-Raygani A; Madani H; Malek-Khosravi S; Parsian A
Blood Coagul Fibrinolysis; 2009 Jun; 20(4):252-6. PubMed ID: 19349859
[TBL] [Abstract][Full Text] [Related]
52. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis.
Ricart JM; Ramón LA; Vayá A; España F; Santaolaria ML; Todolí J; Castelló R; Fontcuberta J; Estellés A
Br J Haematol; 2008 May; 141(5):716-9. PubMed ID: 18341631
[TBL] [Abstract][Full Text] [Related]
53. Assessment of the role of thrombin activatable fibrinolysis inhibitor in retinal vein occlusion.
Gumus K; Kadayifcilar S; Eldem B; Ozcebe O
Retina; 2007 Jun; 27(5):578-83. PubMed ID: 17558319
[TBL] [Abstract][Full Text] [Related]
54. [ABO/H blood groups and factor V Leiden].
Matýsková M; Zavrelová J; Pejchalová A; Meluzinová H; Janků L
Cas Lek Cesk; 2002 Mar; 141(5):146-51. PubMed ID: 11998221
[TBL] [Abstract][Full Text] [Related]
55. Association of inherited thrombophilia with embryonic and postembryonic recurrent pregnancy loss.
Ivanov PD; Komsa-Penkova RS; Konova EI; Kovacheva KS; Simeonova MN; Popov JD
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):134-40. PubMed ID: 19786941
[TBL] [Abstract][Full Text] [Related]
56. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis.
de Bruijne EL; Darwish Murad S; de Maat MP; Tanck MW; Haagsma EB; van Hoek B; Rosendaal FR; Janssen HL; Leebeek FW;
Thromb Haemost; 2007 Feb; 97(2):181-5. PubMed ID: 17264944
[TBL] [Abstract][Full Text] [Related]
57. Thrombophilic factors are not the leading cause of thrombosis in Behçet's disease.
Leiba M; Seligsohn U; Sidi Y; Harats D; Sela BA; Griffin JH; Livneh A; Rosenberg N; Gelernter I; Gur H; Ehrenfeld M
Ann Rheum Dis; 2004 Nov; 63(11):1445-9. PubMed ID: 15479893
[TBL] [Abstract][Full Text] [Related]
58. Early postoperative obstructive prosthetic mitral valve thrombosis in a patient double heterozygous for factor V Leiden and prothrombin G20210A mutation.
De Paulis S; Rossi E; Zamparelli R; Scapigliati A; Corrado M; De Stefano V
Thromb Haemost; 2008 Feb; 99(2):441-2. PubMed ID: 18278197
[No Abstract] [Full Text] [Related]
59. The prevalence of inherited thrombophilic polymorphisms in an asymptomatic Australian antenatal population.
Said JM; Brennecke SP; Moses EK; Walker SP; Monagle PT; Campbell J; Bryant VJ; Borg AJ; Higgins JR
Aust N Z J Obstet Gynaecol; 2008 Dec; 48(6):536-41. PubMed ID: 19133039
[TBL] [Abstract][Full Text] [Related]
60. The impact of inherited prothrombotic risk factors on individuals chronically infected with hepatitis C virus from a single source.
Goulding C; O'Brien C; Egan H; Hegarty JE; McDonald G; O'Farrelly C; White B; Kelleher D; Norris S
J Viral Hepat; 2007 Apr; 14(4):255-9. PubMed ID: 17381717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
